Champions Oncology, Inc.

NasdaqCM:CSBR Stock Report

Market Cap: US$58.7m

Champions Oncology Future Growth

Future criteria checks 4/6

Champions Oncology is forecast to grow earnings and revenue by 146.9% and 9.6% per annum respectively.

Key information

146.9%

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth18.3%
Revenue growth rate9.6%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Sep 2024

Recent future growth updates

Recent updates

Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

Oct 24
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Jun 14
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Sep 28
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Jul 21

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21
We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09
Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02
The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04
Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Earnings and Revenue Growth Forecasts

NasdaqCM:CSBR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
4/30/202765N/A-1N/A1
4/30/20265910N/A1
4/30/20255411N/A1
7/31/202452-3-2-2N/A
4/30/202450-7-7-6N/A
1/31/202449-10-7-5N/A
10/31/202350-10-5-3N/A
7/31/202353-8-30N/A
4/30/202354-514N/A
1/31/202354-335N/A
10/31/202254068N/A
7/31/202252046N/A
4/30/202249146N/A
1/31/202247014N/A
10/31/2021440-40N/A
7/31/2021430-4-1N/A
4/30/2021410-5-2N/A
1/31/202139-1-13N/A
10/31/202037-203N/A
7/31/202035-102N/A
4/30/202032-213N/A
1/31/202031001N/A
10/31/201929-112N/A
7/31/201928-101N/A
4/30/201927012N/A
1/31/201924012N/A
10/31/201823001N/A
7/31/201821011N/A
4/30/201820-1N/A-1N/A
1/31/201819-3N/A-1N/A
10/31/201718-5N/A-2N/A
7/31/201717-5N/A-2N/A
4/30/201715-7N/A-3N/A
1/31/201715-7N/A-4N/A
10/31/201614-8N/A-4N/A
7/31/201612-10N/A-6N/A
4/30/201611-10N/A-6N/A
1/31/201612-12N/A-8N/A
10/31/201511-12N/A-10N/A
7/31/201510-13N/A-9N/A
4/30/20159-13N/A-10N/A
1/31/20158-12N/A-7N/A
10/31/201410-10N/A-7N/A
7/31/201410-9N/A-4N/A
4/30/201412-7N/A-3N/A
1/31/201411-7N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSBR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CSBR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CSBR is expected to become profitable in the next 3 years.

Revenue vs Market: CSBR's revenue (9.6% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CSBR's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time


Discover growth companies